Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

EDX Medical Group (LSE:EDX) Dips as Diagnostics Ambitions Run Ahead of Revenue

EDX Medical Group plc (LSE:EDX) is a Cambridge-based developer of digital diagnostic products and services aimed at personalised treatment for cancer, heart disease and infectious diseases. Founded by life sciences entrepreneur Professor Sir Christopher Evans and chief executive Dr Mike Hudson, the company moved …

Ankur Sharma | 22 October 2026

Abingdon Health (LSE:ABDX) Extends Slide as Going-Concern Caution Tempers Growth Story

Abingdon Health plc (LSE:ABDX) is an international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech. Specialising in lateral flow technology, it takes customer projects from concept to routine manufacturing. The group is headquartered in York, with laboratories in Doncaster and …

Ankur Sharma | 22 October 2026

Oxford Nanopore Technologies PLC (LSE:ONT): Margin Progress and Sequencing Adoption Support Recovery Optimism

The latest interim results showed revenue growth, higher gross margins and narrower operating losses, supported by manufacturing improvements and cost discipline. Liquidity remained substantial but declined as operations consumed cash. Commercial progress in clinical and biopharmaceutical workflows contrasted with weaker activity in China. A …

Ankur Sharma | 22 October 2026

SkinBioTherapeutics (LSE:SBTX) Under Pressure as Cash Concerns Shadow Its Recovery Effort

SkinBioTherapeutics plc (LSE:SBTX) is an AIM-quoted life science company focused on skin health. It develops products based on its SkinBiotix microbiome platform, sells the AxisBiotix range of food supplements and owns the Dermatonics foot-care brand. It has also expanded into contract manufacturing through an …

Ankur Sharma | 22 October 2026

Can Halma plc Sustain Growth as Investors Scrutinise Valuation? (HLMA)

Halma plc (LSE:HLMA) is in focus as investors weigh company fundamentals against a changing UK market backdrop. For the FTSE 100, the broader setting on 22 October 2026 includes renewed sensitivity to inflation, bond yields, interest-rate expectations and corporate earnings. That environment can produce …

Ankur Sharma | 22 October 2026

International Biotechnology Trust PLC (LSE:IBT): Why Clinical Trial Catalysts Could Put This London Stock in Focus on 22 October 2026

The most useful lens for International Biotechnology Trust PLC is the interaction between clinical trial catalysts and company-specific execution. On 22 October 2026, investors assessing London-listed shares face a market shaped by persistent inflation, the prospect of tighter monetary policy and uneven sector demand. …

Ankur Sharma | 22 October 2026

Biotech Growth Trust PLC (LSE:BIOG): Why Drug Development Sentiment Could Put This London Stock in Focus on 22 October 2026

The most useful lens for Biotech Growth Trust PLC is the interaction between drug development sentiment and company-specific execution. On 22 October 2026, investors assessing London-listed shares face a market shaped by persistent inflation, the prospect of tighter monetary policy and uneven sector demand. …

Ankur Sharma | 22 October 2026

Creo Medical Group PLC (LSE:CREO): Advanced Energy Adoption Encourages Cautious Recovery Optimism

The latest available trading communication highlighted strategic progress, a lower operating cost base and continued clinical and commercial activity. Management maintained confidence in annual guidance at that update. These developments support recovery interest in the core technology, but adoption must be assessed through repeat …

Ankur Sharma | 22 October 2026

ValiRx PLC (LSE:VAL): Why This Aim Healthcare Stock Deserves Attention on 22 October 2026

The relevant market is London’s AIM growth market. Inclusion in the AIM market does not itself establish membership of a benchmark index or a positive share-price move.

Ankur Sharma | 22 October 2026

ValiRx PLC (LSE:VAL): Why This AIM Stock Is in Focus on 22 October 2026 and What Comes Next

The principal identifiable area of investor interest is partnering and development progress. This is a focus area, not confirmation that a fresh price-moving announcement occurred today.

Ankur Sharma | 22 October 2026
Support

Hi! How can we help you today?

Loading…